Anupam Rasayan to acquire 43.3% stake in Bliss GVS Pharma
Anupam Rasayan will take control of Bliss GVS after signing a deal for a 43.3% stake at ₹299 per share, triggering a ₹829 crore mandatory open offer.
What's new
- Anupam Rasayan buys a 43.3% stake in Bliss GVS for ₹1,370 crore.
- A mandatory open offer for an additional 26% of equity is now live at ₹299 per share.
- The transaction marks a total change in control and promoter reclassification.
Why this matters
This deal is a complete reversal of recent company denials regarding potential acquisition rumors. With a total deal value of over ₹2,198 crore and an open offer representing 26% of current market capitalization, the ownership shift is as material as it is sudden.
What we're watching
- Regulatory approval timelines for the change in control.
- The official reclassification of existing promoters as public shareholders.
- Future strategic shifts under the new promoter.
The full read
Bliss GVS Pharma is changing hands. Anupam Rasayan India has signed a share purchase agreement to acquire a 43.3% stake in the company for ₹1,370 crore, or ₹299 per share. The move triggers a mandatory open offer for another 26% of equity, worth up to ₹829 crore. The total transaction value exceeds ₹2,198 crore. For context, the open offer alone accounts for roughly 26% of the company’s current ₹3,176 crore market capitalization. This deal marks a fundamental shift in control and governance, as Anupam Rasayan becomes the new promoter and existing promoters move to the public category. The development follows recent company denials that such a deal was in the works. With regulatory approvals pending, the focus shifts to how the new leadership will redefine the firm's strategic direction after this surprise acquisition.
Questions answered
- What is the total valuation of the transaction?
- The combined value of the stake purchase and the mandatory open offer is over ₹2,198 crore.
- Is the open offer conditional on minimum acceptance?
- No. The mandatory open offer for 26% of equity is not subject to any minimum acceptance level.
- How does this change the ownership structure?
- Anupam Rasayan will become the new promoter of Bliss GVS Pharma, while the existing promoter group will be reclassified as public shareholders.
- Why is this deal considered unexpected?
- The company previously issued clarifications that denied any such acquisition was taking place, making this sudden agreement a reversal of its stated position.